Stock repurchase programs often signal to the market that the company's leadership believes its stock is undervalued. This can lead to increased investor confidence and potentially support or increase the stock price in the short term. Given the specific authorization to purchase up to $1M in common stock until April 30, this shows a clear intent by Silo Pharma to invest in its own shares, which could be perceived positively by the market.